Trial Profile

Vorinostat to Augment Response to Lutetium-PSMA-617 in the Treatment of Patients With PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Vorinostat (Primary) ; Vorinostat (Primary) ; Fludeoxyglucose F-18; Gallium (68Ga) gozetotide
Indications Adenocarcinoma; Carcinoma; Prostate cancer
Focus Pharmacodynamics

Most Recent Events

13 Sep 2024 Planned initiation date changed from 21 Sep 2024 to 1 Sep 2024.
23 Aug 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Sep 2024 to 21 Sep 2024.
23 Aug 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com